Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Chemistry World September 2009	Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
Chemistry World January 2012	Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Chemistry World January 2008 Derek Lowe	Column: In the Pipeline It's been a rough year, but the future looks bright for pharma.
Bio-IT World Jul/Aug 2006 Eric K. Neumann	Combining Drug Toxicity Knowledge Nearly half the drugs entering clinical trials will fail because of some form of serious toxicity that was missed in preclinical studies. These failures should not happen at such a late stage in the process. So what can be done?
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool September 24, 2007 Brian Lawler	An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.
Chemistry World July 31, 2013 Daniel Johnson	Animal testing failures put drug trial volunteers in danger The reporting of animal studies is biased, inflating the efficacy of drug candidates and pushing them into the clinic before they are ready.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
Bio-IT World April 16, 2004	Best of the Best, Sir The FDA wants to change its ways and share its accumulated wisdom as part of a focused attack on costly, unpredictable product development.
Chemistry World November 2006 Derek Lowe	Opinion: In the Pipeline Is there a way to kill off bad drug candidates before companies invest valuable time and money and in them?
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
BusinessWeek September 23, 2010 Rob Waters	Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Pharmaceutical Executive November 1, 2014 William Looney	Pharma Science: It's Hard Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.
The Motley Fool June 6, 2006 Brian Lawler	Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines.
Bio-IT World August 18, 2004 John Russell	Curbing a Killer Iconix Pharmaceuticals is working on building biomarkers that can predict toxicity and efficacy.
Bio-IT World April 2007 Malorye Allison	Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines?
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
Food Processing March 2009 Diane Toops	Kraft Foods Global Thinks Outside the Box with Bioactive Ingredients Kraft hires a pharmaceutical company to help it develop functional foods.
Chemistry World December 22, 2006 Victoria Gill	Metabolic Profiling Could Improve Animal Experiments Different types of rats respond to drugs in substantially different ways that can be tracked by metabolic analysis, according to scientists who say their finding has major implications for designing animal experiments.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
Chemistry World November 2009 Derek Lowe	Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times
The Motley Fool February 7, 2005 Stephen D. Simpson	Axonyx Gets Crushed The biotech company is hammered by disappointing phase 3 results of an Alzheimer's drug.
The Motley Fool November 30, 2007 Brian Orelli	Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
Chemistry World July 2, 2013 Derek Lowe	Target acquired Phenotypic screening has recently seen a revival in popularity. This technique assesses drug candidates first by their effects in some organism, then works back to their causes. It can be an effective strategy, but when you find some interesting results, the need to explain them can become acute.
Bio-IT World November 14, 2003 Malorye Branca	Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
The Motley Fool August 4, 2010 Mac Greer	One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Chemistry World April 2006 Karen Harries-Rees	Editorial: Drugs Testing on Trial A drugs trial in the UK that went disastrously wrong last month has raised questions about the ethics of using paid volunteers in clinical trials and the usefulness of animal testing.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.